Relations of mediators of inflammation and hemostasis with preclinical atherosclerosis have been poorly analyzed. The aim of this study was to test potential associations of these blood markers with indicators of cardiovascular risk and atherosclerotic burden in asymptomatic, nonsmoking, hypercholesterolemic men.
A dvances in the molecular and cellular basis of inflammation and hemostasis have led to identify several circulating mediators that might play a critical role in the initiation and development of atherosclerotic disease and its clinical complications. Most of these mediators have been identified as markers associated with advanced complicated atherosclerosis in symptomatic patients, but their potential relation with preclinical early atherosclerosis in asymptomatic subjects has been still poorly analyzed. [1] [2] [3] This lack underscores the need for better studying whether markers from inflammation and hemostasis network may reflect a high atherosclerotic burden at the initial stage of arterial disease before symptomatic complications. Therefore, studying the circulating forms of cytokines, adhesion molecules, and hemostatic factors to analyze their respective roles in the early devel-opment of the atherosclerotic disease is of major interest. The purpose of the present work was to test potential associations between this panel of circulating molecules related to inflammation and hemostasis and indicators of cardiovascular risk and preclinical atherosclerotic burden as reflected by the 10-year Framingham risk, 4 ultrasoundassessed extracoronary plaques, 5 and intima-media thickness (IMT) 6 in a well characterized, hospital-based cohort of asymptomatic, nonsmoking, hypercholesterolemic men.
Methods

Subjects
A total of 87 subjects were recruited consecutively in the department of cardiovascular preventive medicine (Broussais Hospital). Each subject underwent careful selection to fulfill the following criteria: male sex; LDL cholesterol Ͼ3.34 mmol/L; absence of current smoking defined by one or more cigarettes per day each day within the last 3 months; absence of current or past history of known inflammatory or auto-immune disease and of current (within the last month) infectious disease including antibiotic therapy; absence of current therapy with lipid lowering, antihypertensive, antidiabetic, anti-inflammatory, or antiaggregant drugs; absence of present or past history of symptomatic cardiovascular disease. The study was approved by local ethical committee, and written informed consent was obtained from all patients.
Risk Factor Evaluation
All subjects underwent measurements of clinical and biological risk factors (Table 1) . Body mass index was calculated as the ratio between weight and height squared. Supine blood pressure (BP) was measured in the brachial artery, using a sphygmomanometer, after the subject had rested for 10 min. Total cholesterol (TC), HDL cholesterol (HDL-C) after precipitation of VLDL, as well as LDL and triglycerides (TG) were measured after overnight fast with routine automated enzymatic methods. Blood glucose and plasma insulin were measured after overnight fasting. The 10-year Framingham risk was calculated by means of the Anderson equation. 4 Two groups were constituted according to Framingham risk below (low Framingham risk group) or above (high Framingham risk group) the median value of the distribution, that is, 9%. Values for the above clinical and biological parameters are shown in Table 1 .
Arterial Measurements
Arterial measurements were performed by one experienced sonographer physician (N.D.) with high-resolution B-mode ultrasonographic imager (HDI 5000, ATL, Les Ullis, France).
Presence of plaque was assessed at three arterial sites: 1) carotid on both sides, 2) abdominal aorta in its overall length, and 3) femoral on both sides. Plaque was defined 5 as a focal echogenic encroachment into the lumen Ͼ1.5 mm. Number of sites with plaques was counted and reported as 0, 1, 2, or 3 regardless of the location and number of plaques. 5 Average IMT was assessed as the mean of IMT measurement at four sites: right and left common carotid and femoral arteries. The IMT was measured in the far wall of the artery at the end-diastole (electrocardiographic triggering), with an automated edge-detection computerized program (Iôtec, IôDP, Paris, France). 6 A high IMT was defined as IMT value above the median value of IMT distribution (0.53 mm). Values of arterial parameters are shown in Table 1 .
Circulating Markers
All these blood markers were simultaneously measured for all patients at the end of recruitment period from venous blood samples obtained after overnight fasting, immediately separated into serum, plasma ethylenediaminetetraacetate (EDTA) and citrated plasma, and frozen in aliquots at Ϫ80°C. Each sample was tested in duplicate. The CRP was measured in serum by high-sensitivity immunonephelometry (Dabe Behring Marburg GmbH, Marburg, Germany). Both IL-10 and TNF-␣ were mea- 14 (16) Values are mean Ϯ SD, or number (n) with percentage (%). HDL-C ϭ HDL cholesterol; IMT ϭ intima-media thickness; TC ϭ total cholesterol; TG ϭ triglycerides.
sured in plasma by Quantikine high sensitivity human IL-10 and TNF-␣ (R&D Systems, Abington, UK). Detection limits were respectively 0.5 pg/mL and 0.10 pg/mL. Plasma factor VIIc was measured by chronometrical method (Asserachrom, Diagnostica stago, Asnières, France). Fibrinogen was measured in plasma by the Clauss method with an automated device (Diagnostica Stago, Asnière, France). Both PAI-1 and von Willebrand factor (vWF) were measured in plasma by ELISA (Asserachrom, Diagnostica Stago, Asnières, France). Both sICAM-1 and sPselectin were measured in plasma by ELISA Quantikine human sICAM-1 and sP-selectin (R&D Systems, Abington, UK). Detection limits were respectively 0.35 ng/mL and 0.5 ng/mL. vWF levels were corrected for ABO blood groups.
Statistical Analysis
Univariate comparisons between groups were performed with analysis of variance. Univariate correlations between parameters were performed with a least-squares regression model. Multivariate analysis were performed with logistic regression model. Normal distribution was tested for each parameter with the Shapiro-Wilks W test. Logarithmic transformation was used for circulating markers with skewed distribution. Statistical significance was set at values of P Ͻ .05.
Results
Inter-Relationships Between Circulating Markers
Positive correlations were found between the following: CRP and fibrinogen (r ϭ 0.28, P Ͻ .01); CRP and PAI-1 (r ϭ 0.50, P Ͻ .001); IL-10 and TNF-␣ (r ϭ 0.26, P Ͻ .05); IL-10 and fibrinogen (r ϭ 0.28, P Ͻ .05); factor VIIc and PAI-1 (r ϭ 0.30, P Ͻ .01); sICAM-1 and PAI-1 (r ϭ 0.30, P Ͻ .01); and vWF and fibrinogen (r ϭ 0.31, P Ͻ .01).
Relationships Between Circulating Markers and Cardiovascular Risk
Blood pressure was associated with CRP (positively for systolic and diastolic BP, P Ͻ .01, P Ͻ .05) and with vWF (negatively for systolic BP only, P Ͻ .05) ( Table 2 ). Blood lipids were associated significantly with factor VIIc (positively for TC and TG, P Ͻ .01); with PAI-1 (positively for TC, P Ͻ .01, TC/HDL-C, P Յ .001 and for TG, P Ͻ .001, and negatively for HDL-C, P Ͻ .01); and with sP-selectin (positively for TC, TC/HDL-C, P Յ .05 and TG, P Ͻ .05 (Table 2) .
Framingham risk score was associated significantly with CRP (r ϭ 0.23, P Ͻ .05), PAI-1 (r ϭ 0.34, P Ͻ .01), and sP-selectin (r ϭ 0.28, P Ͻ .05), resulting in higher values of CRP, PAI-1, and sP-selectin in subjects with high Framingham risk than in those with low Framingham risk (P Ͻ .05) ( Table 3) .
Significant positive associations persisted between high Framingham risk and CRP (P Ͻ .05), PAI-1 (P Ͻ .001), sICAM-1 (P Ͻ .05), and sP-selectin (P Ͻ .05) after age-adjustment (Model 1, Table 4 ). High Framingham risk remained associated positively with PAI-1 (P Ͻ .05), sICAM-1 (P Ͻ .05) and sP-selectin (P Ͻ .01) after adjustment for age and body mass index (Model 2, Table 4 ). Positive association between high Framingham risk and sP-selectin persisted after adjustment for Model 2 covariates plus TG and plasma insulin, (P Ͻ .05, Model 3, Table 4 ).
Logistic regression analysis of high Framingham risk on all circulating markers, after adjustment for ABO group, age, body mass index, triglycerides, and plasma insulin showed that only sP-selectin remained associated positively and independently with high Framingham risk (P Ͻ .05). The odd ratio (95% confidence intervals) of having high Framingham risk per 1-SD increase in sP-selectin was 3.38 (1.43 to 10.21) . No other association between markers and high Framingham risk persisted. Data are regression coefficients. BP ϭ blood pressure; CRP ϭ C-reactive protein; IL ϭ interleukin; PAI ϭ plasminogen activity inhibitor; SBP ϭ systolic blood pressure; sICAM-1 ϭ soluble intercellular adhesion molecule-1; sP-selectin ϭ soluble P-selectin; TNF ϭ tumor necrosis factor; vWF ϭ von Willebrand factor; other Abbreviations as in Table 1 . * P Ͻ .01; † P Ͻ .05; ‡ P Ͻ .001. Values are means (SD). n ϭ Number of subjects; other abbreviations as in Table 2 . * Log-transformed for statistical analysis; † P Ͻ .05; ‡ P Ͻ .01. Tables 1 and 2 . * Log-transformed for statistical analysis; † P Ͻ .05; ‡ P Ͻ .001; § P Ͻ .01. Table 3 shows that, in univariate analysis, subjects with three-site plaques had higher sP-selectin (P Ͻ .05) than those without three-site plaques and that subjects with high IMT had higher CRP (P Ͻ .05) and PAI-1 (P Ͻ .05) than those with low IMT. Association of CRP with IMT remained significant when IMT was expressed as a continuous variable (r ϭ 0.26, P Ͻ .05), whereas that of PAI-1 became not significant. Analysis of patients with only one-site plaque (carotid, femoral, or aortic) showed that CRP and sP-selectin were higher in the presence than in the absence of carotid plaque (P Ͻ .05). No difference in any circulating marker existed by presence or absence of aortic or femoral plaque. Among circulating markers, only sP-selectin was positively associated with the number of sites with plaque (P Ͻ .05) (Fig. 1) . Table 4 shows that, after age adjustment (Model 1), significant positive association persisted between threesite plaques and sP-selectin (P Ͻ .05). After adjustment for age, body mass index, systolic BP, TC/HDL, and blood glucose (Model 2), three-site plaques remained almost significantly associated with sP-selectin (P ϭ .06). After adjustment for Model 2 covariates plus TG and plasma insulin, positive association almost persisted between three-site plaques and sP-selectin (P ϭ .06). No adjusted associations were found between each circulating marker and high IMT.
Relationships Between Circulating Markers and Atherosclerosis
After adjustment for all the above covariates and for ABO blood groups, sP-selectin remained associated with three-site plaques, positively and independently of all other circulating markers (P Ͻ .05). The odd ratios (95% confidence intervals) of having presence of three-site plaques per 1-SD increase in sP-selectin was 5.23 (1.74 to 23.52).
Discussion
Our main finding was to observe, for the first time to our knowledge, that sP-selectin blood level was positively and independently associated with two preclinical markers of atherosclerotic risk and burden, namely high Framingham risk and the presence of plaques at three extracoronary sites (three-site plaques). We obtained this result in a highly selected cohort of asymptomatic men with isolated hypercholesterolemia, the most common condition of increased cardiovascular risk in primary prevention. We paid special attention to exclude any associated factor likely to influence the potential association of sP-selectin and other markers with arterial markers of atherosclerotic risk. Among them, current smoking was absolutely excluded because it directly alters markers of inflammation and hemostasis, 7, 8 as well as arterial markers of atherosclerotic risk. The taking into account of exhaustive exclusion criteria explains that the size of our study population was smaller than other literature studies in the field where such exclusion criteria were not applied.
The associations of sP-selectin with high Framingham risk, and presence and extent of atherosclerosis, both predictors of cardiovascular complications, 3, 5 are consistent with a recent study showing that sP-selectin was positively correlated with the occurrence of clinical events, independently of traditional cardiovascular risk factors. 9 Nevertheless, our associations were obtained at a preclinical phase of atherosclerotic disease, independently of the future cardiovascular events, and therefore deserve several specific comments. First, the positive associations of sPselectin with TC and TG agree with the previous finding that sP-selectin level is increased in plasma of hypercholesterolemic subjects free of symptoms. 10 The association of sP-selectin with high Framingham risk, an index of the combined influence of total and HDL cholesterol and BP, suggests that the effect of lipid profile alteration on sPselectin may be potentiated by BP; but in the present work, sP-selectin was not associated with BP. Second, the association of sP-selectin with carotid plaque and overall three-site plaques provides evidence of the increase in the circulating level of this molecule at the early stage of atherosclerosis. The possibility that hypercholesterolemia in our patients could represent a state responsible for the increase of inflammatory substances such as sP-selectin, thus confounding its predictive influence on atherosclerosis, is excluded by the persistence of associations of sPselectin with atherosclerosis after adjustment for TC to HDL-C ratio and after adjustment for TG. However, it contrasts with the lack of association between sP-selectin and high IMT, reflecting the very early hypertrophic process of the arterial wall.
11 P-selectin is an adhesion molecule of the plasma membrane of platelets ␣ granules and endothelial Webel-Palade bodies, expressed both on activated platelets and endothelial cells. P-selectin could play a role on atherosclerotic burden, especially the diffusion of extracoronary atherosclerotic plaques at multiple sites, by adhesion of leukocytes on activated endothelial cells. 12 The lack of univariate correlation between sP-selectin and the von Willebrand factor, a marker of activated endothelial cells, suggests that sP-selectin could rather reflect the activation of platelets in our population. It has been recently shown in mice that platelet P-selectin facilitates atherosclerotic lesion development. 13 In addition sP-selectin is able to induce the release of procoagulant microparticles in mice, 14 but we did not observe any correlation between sP-selectin and factor VIIc for supporting this phenomenon in our patients.
A second interesting finding was that another adhesion molecule tested in our work, sICAM-1, was positively associated with high Framingham risk in multivariate analyses. However, this association disappeared with additional adjustment for triglycerides and plasma insulin because both parameters were strongly correlated with sICAM-1. The association of sICAM-1 with high Framingham risk may be explained by the fact that ICAM-1 reflects inflammation and endothelial status, which may be affected by high Framingham risk. In the current study sICAM-1 was not associated with the presence of threesite plaques and, like sP-selectin, it was not associated with high IMT. These findings are somewhat discrepant with a previous study of the literature showing that sICAM-1 was superior to sP-selectin with regard to the prediction of clinical events. 15 However, the population of this study was different from ours in that it included exclusively women, some of whom developing subsequent cardiovascular complications. Experimental studies have shown that the complete absence of P-selectin, but not ICAM-1, markedly reduced plaque and suggested that P-selectin, but not ICAM-1, was critical for monocyte recruitment to sites of neointimal formation. 16 Besides sP-selectin and sICAM-1, we have tested a panel of mediators of inflammation and hemostasis, including the most recognized markers reflecting the interactions between endothelial and blood cells on the arterial wall. Surprisingly, CRP was less strongly associated with arterial markers than sP-selectin. In a univariate analysis, it correlated positively with BP, high Framingham risk, and high IMT but not with three-site plaques; however, after adjustment for the study covariates, the association of CRP with high Framingham risk and high IMT disappeared. The weakness and unstability of these associations are contradictory with previous results in symptomatic and even asymptomatic subjects. 17, 18 Similarly, we found no association between fibrinogen and arterial parameters, although there was a trend for higher fibrinogen in high Framingham risk and three-site plaque groups. This lack is discrepant with the well established value of fibrinogen as an independent cardiovascular risk factor 19 and with our previous findings showing that fibrinogen was associated with extracoronary plaques and coronary calcifications in asymptomatic subjects. 20 Nevertheless, such studies included substantial proportions of smokers, and it is likely that the exclusion of current smoking from our present study population may have attenuated the associations of fibrinogen and CRP with arterial risk markers. 7, 8 We also found that cytokines regulating inflammation (TNF-␣, IL-10) were not associated with arterial parameters although they were correlated with some other markers. The correlation of fibrinogen with IL-10, and of IL-10 with TNF-␣ may reflect a proinflammatory condition, with the anti-inflammatory cytokine IL-10 allowing us to consider the possibility of anti-inflammatory feedback at the early stage of arterial lesions. 21, 22 It is interesting to note that we observed a strong correlation between CRP and PAI-1, because it has been recently shown that, in vitro, CRP itself induces PAI-1 expression and activity in human aortic endothelial cells. 23 Finally, blood CRP, sP-selectin, sICAM-1, and PAI-1, which were associated with high Framingham risk, are markers of both inflammation and cell activation. Factor VIIc was not associated with arterial parameters, probably because it concerns rather advanced stages of atherothrombotic disease.
Study Limitations
Our findings were obtained in a very selected population using transverse analysis. Moreover, the small number of subjects may negatively influence the statistical strength of data and may be responsible for the lack of correlation between markers other than sP-selectin and preclinical atherosclerosis. Therefore, further prospective studies are required in larger populations to follow the blood levels of the relevant markers and to assess the very early interest of sP-selectin in asymptomatic patients at risk for atherosclerosis.
In conclusion, the cross-sectional research of potential associations between a panel of markers of inflammation and hemostasis and several parameters of integrated atherosclerotic risk (10-year Framingham risk, three-site extracoronary plaques, and IMT) within a population of asymptomatic, nonsmoking, hypercholesterolemic men shows that among all markers tested, only sP-selectin exhibited a consistent and independent association with atherosclerotic risk burden. This association suggests that sP-selectin might be a useful marker of preclinical atherosclerosis.
